DIM (Diindolylmethane) — Frequently Asked Questions
This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer
Frequently Asked Questions
What is the difference between DIM and I3C supplements?
What is the difference between DIM and I3C supplements?
DIM is actually a metabolite of I3C — when you consume I3C (from supplements or cruciferous vegetables), your stomach acid converts it into several compounds, with DIM being the most important for estrogen metabolism. Taking DIM directly bypasses this conversion step, providing a more predictable and consistent dose. I3C conversion is variable and also produces other metabolites. Most experts now recommend DIM over I3C for more reliable estrogen metabolism modulation.
Why does DIM change urine color?
Why does DIM change urine color?
DIM and its metabolites are chromophores (colored compounds). When excreted in urine, they produce a darker amber-to-brownish color that can be alarming but is completely harmless. This discoloration confirms that DIM is being absorbed and metabolized. The color change is more noticeable with enhanced-absorption forms due to higher bioavailability. It does not indicate kidney problems or dehydration.
Can men take DIM?
Can men take DIM?
Yes. While DIM is often marketed toward women, men also metabolize estrogen, and the 2:16α-OHE1 ratio is relevant to men's health. DIM may help men maintain healthy estrogen metabolism, particularly those concerned about estrogen dominance or using testosterone replacement therapy. Some practitioners recommend DIM for men on TRT to help manage estrogen conversion. The typical dose for men is the same — 100-200mg enhanced-absorption DIM daily.
References
- Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF (2004). Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and Cancer. DOI PubMed
- Thomson CA, Chow HHS, Wertheim BC, et al. (2017). A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. DOI PubMed